2025-12-21 - Analysis Report
Here's a comprehensive analysis of Northrop Grumman (NOC) based on the provided data:

**1) Return Rate Comparison:**

*   **Company Overview:** Northrop Grumman Corp is a global aerospace and defense technology company.
*   **Return Rate:** NOC's cumulative return is 47.50%, significantly underperforming the S&P 500 (VOO) which returned 100.88%.
*   **Divergence:**  The current divergence is -52.2. This means NOC is lagging the S&P 500.  The relative divergence of 6.2 indicates that this divergence is near the lower end of its historical fluctuation range.

**Alpha, Beta Analysis:**

| Year      | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|-----------|--------|--------|--------|-------|--------|
| 2015-2017 | 46.0%  | 65.6%  | 17.0%  | 0.0   | 43.9   |
| 2016-2018 | -2.0%  | 74.3%  | -17.0% | 0.0   | 35.1   |
| 2017-2019 | 17.0%  | 79.2%  | -5.0%  | 0.9   | 49.2   |
| 2018-2020 | -28.0% | 79.9%  | -52.0% | 0.8   | 43.6   |
| 2019-2021 | 43.0%  | 79.9%  | -4.0%  | 0.8   | 55.4   |
| 2020-2022 | 18.0%  | 79.9%  | 19.0%  | 0.3   | 78.1   |
| 2021-2023 | 24.0%  | 82.7%  | 23.0%  | 0.2   | 67.0   |
| 2022-2024 | -15.0% | 82.7%  | -36.0% | 0.2   | 67.2   |
| 2023-2025 | -3.0%  | 82.1%  | -68.0% | 0.1   | 81.4   |

*   **Analysis:**
    *   **CAGR:**  Varying performance across different periods, with some strong growth years (2015-2017, 2019-2021) and some negative returns (2016-2018, 2018-2020, 2022-2024).
    *   **MDD:** Consistently high Maximum Drawdown indicates significant risk.
    *   **Alpha:** Alpha is often negative, suggesting underperformance relative to its benchmark, especially in recent years.  The negative alpha suggests NOC isn't generating excess returns based on its risk (Beta).
    *   **Beta:**  Beta is generally low, indicating lower volatility than the market.  The decreasing beta trend suggests the stock has become less sensitive to market movements over time.
    *   **Cap(B):**  The market capitalization has varied over the periods.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 568.46
*   **Previous Close:** 559.52
*   **Change:** +1.6% (reflects some positive fluctuation)
*   **5-day SMA:** 567.34
*   **20-day SMA:** 560.77
*   **60-day SMA:** 581.32

*   **Analysis:**
    *   The price is currently above both the 5-day and 20-day SMAs, suggesting a short-term upward trend. However, the price is below the 60-day SMA, indicating a possible weakening of the longer-term uptrend.

**3) Indicators Analysis:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 65.35 (Approaching overbought territory - usually above 70)
*   **PPO:** 0.39
*   **Hybrid Signal:** Buy 100% of cash (4 shares - Very Safe - MRI:0.90). The hybrid signal suggests a very safe approach, allocating 100% of cash to purchase a small number of shares, with a target cash ratio of 0% by December 2025.
*   **Recent Relative Divergence Change:** +5.2 (Short-term increase)
*   **Expected Return:** -120.2% (Negative - significant expected underperformance compared to the S&P 500).

*   **Analysis:**
    *   The MRI suggests a medium level of investment risk.
    *   The RSI suggests the stock may be approaching overbought conditions, potentially signaling a pullback.
    *   The significantly negative expected return is a major red flag. This suggests that based on current conditions, long-term investment in NOC is projected to underperform significantly compared to the S&P 500.

**4) Recent News & Significant Events:**

*   **[2025-12-20] Will NOC stock beat Nasdaq index returns:** Questions NOC's potential to outperform the Nasdaq.
*   **[2025-12-20] Northrop Grumman (NOC): Taking Stock of Valuation After a Strong Year-to-Date Share Price Run:**  Evaluates NOC's valuation after a price increase.
*   **[2025-12-18] Northrop Grumman Announces Fourth Quarter and Full-Year 2025 Earnings Release Date and Webcast Details:** Announces upcoming earnings, which can be a catalyst for price movement.
*   **[2025-11-21] Northrop Grumman (NOC): Assessing Value After Recent 5% Pullback in Share Price:**  Looks at NOC's value after a price decrease.
*   **[2025-12-16] YieldBoost NOC From 1.6% To 5% Using Options:**  Discusses strategies to increase yield using options.
*   **[2025-12-18] Northrop Grumman (NOC): Reassessing Valuation After Recent Pullback in a Strong Year for the Stock:** Another reassessment of valuation.

*   **Analysis:**
    *   The news headlines show a mix of perspectives, with some articles questioning the stock's ability to outperform, while others focus on valuation after price movements. The upcoming earnings announcement is a key event to watch.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.04)
*   **Target Price:** Average $662.68 (Significant upside potential from the current price of $568.46)
*   **Recent Rating Changes:** Not specified (but can be inferred from the text to have occurred).

*   **Analysis:**
    *   Analysts, on average, have a "Buy" rating and see significant upside potential based on their target prices. However, it's important to consider the wide range between the high and low target prices ($770 vs $533), indicating uncertainty.

**5) Recent Earnings Analysis:**

| 날짜        | EPS   | 매출       |
|-------------|-------|------------|
| 2025-10-21 | 7.69  | 10.42 B$   |
| 2025-07-22 | 8.17  | 10.35 B$   |
| 2025-04-22 | 3.33  | 9.47 B$    |
| 2024-10-24 | 7.02  | 10.00 B$   |
| 2025-10-21 | 7.02  | 10.00 B$   |

*   **Analysis:**
    *   Revenue has been relatively stable around $10 billion per quarter, with a slight increase in the most recent quarter.
    *   EPS has been more variable, with a lower value in 2025-04-22.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $10.42B    | 21.37%        |
| 2025-06-30   | $10.35B    | 21.35%        |
| 2025-03-31   | $9.47B     | 16.69%        |
| 2024-12-31   | $10.69B    | 18.08%        |
| 2024-09-30   | $10.00B    | 21.07%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE     |
|--------------|-------------|---------|
| 2025-09-30   | $15.99B    | 6.88%   |
| 2025-06-30   | $15.47B    | 7.59%   |
| 2025-03-31   | $14.98B    | 3.21%   |
| 2024-12-31   | $15.29B    | 8.27%   |
| 2024-09-30   | $14.75B    | 6.96%   |

*   **Analysis:**
    *   **Revenue:** Revenue shows some fluctuation quarter to quarter
    *   **Profit Margin:** Profit margins are generally healthy, but had decreased in the 2025-03-31 quarter.
    *   **Equity:** Equity has been trending upwards.
    *   **ROE:** ROE is relatively stable, but also saw a dip in the 2025-03-31 quarter.

**7) Comprehensive Analysis:**

*   **Underperformance:** NOC has significantly underperformed the S&P 500, and the negative expected return suggests this trend may continue.
*   **Risk:**  The high MDD values from the Alpha/Beta analysis points to high risk.
*   **Mixed Signals:** While analysts have a "Buy" rating and see upside potential, the technical indicators and news headlines present a more cautious picture. The RSI is nearing overbought territory, and the recent news highlights valuation concerns.
*   **Financial Health:** While revenue and profit margins are generally strong, the volatility of EPS and the dip in profit margin and ROE in the 2025-03-31 quarter warrant further investigation.
*   **Recommendation:**
Given the underperformance relative to the market, the negative expected return, the nearing overbought RSI, and the mixed news sentiment, a **cautious approach** is warranted.  While analysts are generally positive, the data suggests a potential for continued underperformance. A thorough review of the upcoming earnings release and its impact on the company's future outlook is recommended before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.